CDC advisors voted to lower the minimum age for RSV vaccination. Adults aged 50 to 59 with risk factors may now qualify. The Advisory Committee on Immunization Practices, or ACIP, voted 14-0 in favor. One member voted to abstain.
The recommendation targets adults at high risk of severe RSV symptoms. Qualifying conditions include heart disease, diabetes, asthma, COPD, chronic bronchitis, kidney disease, weakened immunity, and neurological disorders. These health issues are common in people over 50.
How is Expanded Vaccine Access Meant to Help Adults 50-59?
The adjustment would expand the CDC’s current RSV vaccine recommendations. Present guidance advises vaccination for all adults aged 75 and older. Adults 60 to 74 with risk factors are also included. If approved, people with risk factors aged 50 and above will qualify.
Two RSV vaccines, manufactured by GSK and Pfizer, are approved for adults 50 and older. A third vaccine from Moderna awaits FDA approval for this age group.
The panel emphasized the vaccine’s benefits for people with serious conditions. RSV is a major cause of pneumonia in older adults and toddlers. The CDC estimates 15,000 to 20,000 hospitalizations yearly among adults aged 50 to 59.
If the CDC adopts the recommendation, insurance plans will cover costs. Concerns about vaccine cost and effectiveness shaped the panel’s vote. CDC and University of Michigan researchers found targeted use may save money. The strongest benefit applies to people with major chronic conditions.
ACIP approached the expansion of RSV vaccine use with caution. Some reports link Pfizer and GSK vaccines to Guillain-Barré syndrome. No such safety concerns have been reported with Moderna’s vaccine.
RSV vaccine protection appears to decrease over time. Repeat doses increase antibodies but not to initial levels. RSV vaccines are currently considered a one-time shot. However, guidelines may change as new data emerges.
What Other Vaccine Recommendations Did the Panel Make?
The committee also approved several other important vaccine updates. GSK’s new meningitis vaccine, MEN-ABCWY, is now recommended. It’s advised for people aged 16 to 23 and those 10 and older with high-risk medical conditions.
Updated guidelines recommend a new chikungunya vaccine called Vimkunya. The vaccine is for travelers and lab workers at risk of exposure. Bavarian Nordic manufactures Vimkunya, approved for people aged 12 and older. It is intended for outbreak zones or extended stays in high-risk regions.
Finally, ACIP added new warnings for Valneva’s chikungunya vaccine. Six serious side effects were reported in older adults, including five hospitalizations. The vaccine remains approved for people 65 and older, but now includes extra precautions.
Conclusion
The new RSV vaccine recommendation could protect thousands of high-risk adults from RSV. It reflects growing concern about severe illness in the 50–59 age group. Ongoing research will guide future decisions about revaccination and broader access.
Have an upcoming trip? Passport Health offers a wide variety of options to help keep you safe from disease, including vaccines. Call or book online to schedule your appointment today.
Logan Hamilton is a health and wellness freelance writer for hire. He’s passionate about crafting crystal-clear, captivating, and credible content that elevates brands and establishes trust. When not writing, Logan can be found hiking, sticking his nose in bizarre books, or playing drums in a local rock band. Find him at loganjameshamilton.com.
